Literature DB >> 16439722

A protective role for the fifth complement component (c5) in allergic airway disease.

Scott M Drouin1, Meenal Sinha, Georgia Sfyroera, John D Lambris, Rick A Wetsel.   

Abstract

RATIONALE: Reports from our laboratory, as well as those from others, have documented the importance of complement activation, the C3a anaphylatoxin, and its receptor, C3aR, in promoting Th2 effector functions in a mouse model of bronchopulmonary allergy. Although deficiency in the fifth complement component (C5) has been linked to enhanced airway hyperresponsiveness in mice, the contribution of C5 to other major biological hallmarks of asthma has not been evaluated.
OBJECTIVE: Accordingly, congenic C5-sufficient and C5-deficient mice were subjected to a mouse model of bronchopulmonary allergy to assess the impact of C5 on pulmonary inflammation and Th2 effector functions in experimental asthma. METHODS AND MAIN
RESULTS: In contrast to observations reported for C3- and C3aR-deficient animals, C5-deficient mice exhibited significantly increased airway hyperresponsiveness relative to wild-type congenic control mice after antigen challenge. Moreover, challenged C5-deficient mice had a 3.4-fold and 2.7-fold increase in the levels of airway eosinophils and lung interleukin (IL)-4-producing cells, respectively, compared with challenged wild-type mice. Consistent with the numbers of IL-4-producing cells, C5-deficient mice also had increased bronchoalveolar lavage levels of the Th2 cytokines IL-5 and IL-13 and elevated serum levels of total and antigen-specific IgE.
CONCLUSIONS: These data indicate that C5 plays an important protective role in allergic lung disease by suppressing inflammatory responses and Th2 effector functions observed in this experimental model. The protection provided by the presence of C5 is likely mediated by C5a, suggesting that C5a may play a significant role in tempering inflammation in Th2-driven diseases such as asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439722      PMCID: PMC2662907          DOI: 10.1164/rccm.200503-334OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  34 in total

Review 1.  The inhibitory receptor superfamily: potential relevance to atopy.

Authors:  A M Scharenberg
Journal:  Curr Opin Immunol       Date:  1999-12       Impact factor: 7.486

2.  Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma.

Authors:  N Krug; T Tschernig; V J Erpenbeck; J M Hohlfeld; J Köhl
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

Review 3.  Induction and regulation of the IgE response.

Authors:  D B Corry; F Kheradmand
Journal:  Nature       Date:  1999-11-25       Impact factor: 49.962

4.  Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats.

Authors:  M Abe; K Shibata; H Akatsu; N Shimizu; N Sakata; T Katsuragi; H Okada
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy.

Authors:  S M Drouin; D B Corry; J Kildsgaard; R A Wetsel
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

6.  Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma.

Authors:  C L Karp; A Grupe; E Schadt; S L Ewart; M Keane-Moore; P J Cuomo; J Köhl; L Wahl; D Kuperman; S Germer; D Aud; G Peltz; M Wills-Karp
Journal:  Nat Immunol       Date:  2000-09       Impact factor: 25.606

Review 7.  Molecular mechanisms of IgE regulation.

Authors:  L B Bacharier; R S Geha
Journal:  J Allergy Clin Immunol       Date:  2000-02       Impact factor: 10.793

8.  A role for the C3a anaphylatoxin receptor in the effector phase of asthma.

Authors:  A A Humbles; B Lu; C A Nilsson; C Lilly; E Israel; Y Fujiwara; N P Gerard; C Gerard
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

Review 9.  IL-12/IL-13 axis in allergic asthma.

Authors:  M Wills-Karp
Journal:  J Allergy Clin Immunol       Date:  2001-01       Impact factor: 10.793

10.  Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma.

Authors:  W Bautsch; H G Hoymann; Q Zhang; I Meier-Wiedenbach; U Raschke; R S Ames; B Sohns; N Flemme; A Meyer zu Vilsendorf; M Grove; A Klos; J Köhl
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

View more
  24 in total

1.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

Review 2.  Complement activation pathways: a bridge between innate and adaptive immune responses in asthma.

Authors:  Marsha Wills-Karp
Journal:  Proc Am Thorac Soc       Date:  2007-07

Review 3.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

4.  Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma.

Authors:  Elizabeth B Staab; Sam D Sanderson; Sandra M Wells; Jill A Poole
Journal:  Int Immunopharmacol       Date:  2014-05-21       Impact factor: 4.932

Review 5.  Complement and periodontitis.

Authors:  George Hajishengallis
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

6.  Complement C3a regulates Muc5ac expression by airway Clara cells independently of Th2 responses.

Authors:  Patricia Dillard; Rick A Wetsel; Scott M Drouin
Journal:  Am J Respir Crit Care Med       Date:  2007-03-30       Impact factor: 21.405

Review 7.  Complement and the Regulation of T Cell Responses.

Authors:  Erin E West; Martin Kolev; Claudia Kemper
Journal:  Annu Rev Immunol       Date:  2018-04-26       Impact factor: 28.527

8.  C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Authors:  Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 9.  Complement components as potential therapeutic targets for asthma treatment.

Authors:  Mohammad Afzal Khan; Mark R Nicolls; Besiki Surguladze; Ismail Saadoun
Journal:  Respir Med       Date:  2014-01-15       Impact factor: 3.415

10.  The impact of surfactant protein-A on ozone-induced changes in the mouse bronchoalveolar lavage proteome.

Authors:  Rizwanul Haque; Todd M Umstead; Willard M Freeman; Joanna Floros; David S Phelps
Journal:  Proteome Sci       Date:  2009-03-26       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.